Joint EANM, IAEA, and SNMMI practical guidance on somatostatin receptor-targeted radionuclide therapy of neuroendocrine tumours

Lisa Bodei; Gopinath Gnanasegaran; Francesco Giammarile; Marianne Pavel; Valentina Ambrosini; Richard P. Baum; Dieter Hörsch; James R. Howe; Marta Cremonesi; Ghassan El-Haddad; Yuni K. Dewaraja; Thomas A. Hope; David Taieb

doi:10.1016/j.eanmj.2026.100017

Back

Joint EANM, IAEA, and SNMMI practical guidance on somatostatin receptor-targeted radionuclide therapy of neuroendocrine tumours

Journal article

Open access

Joint EANM, IAEA, and SNMMI practical guidance on somatostatin receptor-targeted radionuclide therapy of neuroendocrine tumours

Lisa Bodei, Gopinath Gnanasegaran, Francesco Giammarile, Marianne Pavel, Valentina Ambrosini, Richard P. Baum, Dieter Hörsch, James R. Howe, Marta Cremonesi, Ghassan El-Haddad, …

The EANM Journal, 100017

03/2026

DOI: 10.1016/j.eanmj.2026.100017

Files and links (1)

url

https://doi.org/10.1016/j.eanmj.2026.100017View

Published (Version of record) Open Access

Abstract

Somatostatin analogue-based Peptide Receptor Radionuclide Therapy (PRRT) is a molecularly targeted radiopharmaceutical therapy involving the systemic administration of a radiolabelled octreotide derivative designed to target somatostatin receptors (SST) overexpressed on neuroendocrine tumour (NET) cells. PRRT employing radiolabeled somatostatin receptor agonists [177Lu]Lu-DOTATATE, [177Lu]Lu-DOTATOC and [90Y]Y-DOTATOC has been successfully used for the past 25 years in metastatic or locally advanced inoperable NET. PRRT increases progression-free survival, tumour control, and improvement of most patients' NET-associated functional symptoms and quality of life. Side effects are usually mild to moderate and can be acute/subacute or chronic. The former typically include nausea and fatigue in the immediacy of the administration and subacute transient marrow toxicity, both usually mild to moderate. Chronic effects may involve the kidneys, with renal function impairment typically mainly after 90Y-labelled peptides, and the bone marrow, with the rare occurrence (2-6%) of persistent cytopenias or myelodysplastic diseases. EANM, IAEA, and SNNMI formulated the guidance based on recent literature and experts' opinions. It covers the rationale, indications, and contraindications for PRRT, assessment of treatment response, and patient follow-up. This document aims to guide nuclear medicine specialists in selecting likely candidates to receive PRRT and delivering the treatment safely and effectively.

Safety

guidelines

NET

neuroendocrine tumours

Peptide receptor radionuclide therapy

PRRT

renal protection

Details

Title: Subtitle: Joint EANM, IAEA, and SNMMI practical guidance on somatostatin receptor-targeted radionuclide therapy of neuroendocrine tumours
Creators: Lisa Bodei - Cornell University
Gopinath Gnanasegaran - Royal Free London NHS Foundation Trust
Francesco Giammarile - International Atomic Energy Agency
Marianne Pavel - Friedrich-Alexander-Universität Erlangen-Nürnberg
Valentina Ambrosini - University of Bologna
Richard P. Baum - CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany
Dieter Hörsch - Cancer Genomics Centre
James R. Howe - University of Iowa
Marta Cremonesi - Department of Medical Imaging and Radiation Sciences, European Institute of Oncology, IRCCS, Milan, Italy
Ghassan El-Haddad - Moffitt Cancer Center
Yuni K. Dewaraja - University of Michigan
Thomas A. Hope - University of California, San Francisco
David Taieb - Department of Nuclear Medicine, La Timone University Hospital, Inserm ERL U1326 RNAnoTher, Aix-Marseille Univ, France
Resource Type: Journal article
Publication Details: The EANM Journal, 100017
DOI: 10.1016/j.eanmj.2026.100017
ISSN: 3051-2921
Publisher: Elsevier B.V
Language: English
Electronic publication date: 03/2026
Academic Unit: Surgery
Record Identifier: 9985147077202771

Metrics

1 Record Views